GSK has reinforced its sustainability strategy in the 2025 Annual Report through its “Responsible Business” framework, integrating environmental performance, global health impact, and innovation-led growth into a unified long-term strategy.
At the core of GSK’s sustainability vision is its ambition to positively impact 2.5 billion people by 2030, aligning business growth with global health outcomes. The company’s ESG approach spans environment, access to healthcare, inclusion, ethical standards, and product governance, supported by structured performance tracking. In 2025, 92 percent of its Responsible Business Performance Rating metrics were met or exceeded, highlighting strong execution across sustainability priorities.
“Sustainability is not a separate agenda – it is central to how we innovate, operate responsibly, and deliver long-term value for patients, society, and shareholders,” Luke Miels, Chief Executive Officer of GSK, said.
GSK continues to demonstrate measurable environmental progress alongside healthcare delivery. The company reduced operational carbon emissions (Scope 1 and 2) by 14 percent, advancing toward its long-term ambition of achieving a net zero and nature-positive footprint. In parallel, it delivered 99 million vaccine doses to Gavi-supported programmes, strengthening access to essential healthcare in lower-income markets, according to GSK’s Sustainability Report 2025.
Sustainability at GSK is closely tied to innovation and long-term investment. The company invested £6.6 billion in research and development in 2025, supporting a pipeline of 58 assets, including 17 in late-stage development. This investment is translating into commercial outcomes, with more than £8 billion in sales generated from recently launched medicines. GSK is also advancing next-generation products such as a low-carbon Ventolin inhaler, which has the potential to reduce emissions per inhaler by around 92 percent.
Operational scale remains a critical factor in GSK’s sustainability execution. With 66,800 employees across 70 countries, 33 manufacturing sites, and 18,000 suppliers, the company is embedding sustainability practices across a complex global network. Its responsible supply chain strategy includes sustainability scoring for high-risk suppliers and initiatives such as regional manufacturing and dual sourcing to enhance resilience and reduce environmental and operational risks.
GSK is also leveraging advanced technologies to improve efficiency and sustainability outcomes. The use of AI, digital twins, and data platforms is helping optimize manufacturing processes, reduce resource intensity, and accelerate R&D productivity. At the same time, sustainability performance is linked to executive compensation, ensuring accountability at the leadership level.
GSK’s sustainability-linked investments extend to its Responsible Business framework, where resources are allocated to six focus areas including environment, global health, and ethical standards. Notably, 92 percent of its Responsible Business Performance metrics were met or exceeded in 2025, reflecting consistent funding and execution in sustainability initiatives.
In addition to R&D, GSK is investing in technology-driven transformation, including data platforms, automation, and digital tools across manufacturing and supply chains. These investments are designed to enhance productivity, lower environmental impact, and improve energy efficiency. The company is also prioritizing resilient and regionalized supply chains, enabling reduced emissions and improved sustainability in sourcing and distribution.
The company’s broader strategy connects sustainability with growth by focusing on preventative healthcare, vaccines, and innovative medicines that reduce long-term healthcare burdens. Investments in antimicrobial resistance initiatives, pandemic preparedness, and equitable clinical trials further strengthen its global health impact.
Overall, GSK is positioning sustainability as a core driver of business performance, combining emissions reduction, large-scale healthcare delivery, and sustained R&D investment to deliver long-term societal value while supporting resilient global growth.
BABURAJAN KIZHAKEDATH